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Abstract
Background and purpose. Giant cell tumor (GCT) of the small bones (small-bone GCT) is usually rare and considered
somewhat different from conventional GCT. The purpose of this study was to investigate and report the clinicopathological
features of 11 cases with small-bone GCT.
Materials and methods. Patient information was obtained with the help of questionnaires. X-rays and parafﬁn blocks obtained
from several institutions were clinically, radiographically, and histologically evaluated.
Results. Small-bone GCT was observed in younger patients compared to conventional GCT; 5 of the 11 (45%) patients were
below 20 years of age, whereas the corresponding ﬁgure for all GCT patients is 16% in Japan. Excessive cortical bone
expansion is a special feature. There were two cases of recurrence and one case of lung metastasis; the primary lesion was in the
hand for all three cases. In contrast, no primary lesion of the foot recurred or metastasized. Varying degrees of positive
p63 immunostaining were observed in all examined cases (n = 9) of small-bone GCT but were negative in case of giant cell
reparative granuloma (GCRG) and solid variant of aneurysmal bone cyst (ABC). One case that demonstrated high-
intensity positive staining had two episodes of recurrence.
Conclusion. Small-bone GCT tends to develop in younger patients than does conventional GCT. Primary GCTs of the hand
may be biologically more aggressive than those of the feet. The p63 immunostaining may be useful not only for differential
diagnosis but also for prognostication of small-bone GCT.
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Introduction
Giant cell tumor (GCT) is a relatively common type
of benign bone tumor. Long tubular bones such as the
femur, tibia, and humerus are commonly involved;
however, theoccurrence ofGCT in the hands and feet
is a rare phenomenon. It has been reported that GCT
of the small bones (small-bone GCT) carries a
higher risk of local recurrence and metastasis
than conventional GCT. Although case reports of
small-bone GCT have been reported frequently,
few papers that describe clinicopathological features
of small-bone GCT in a large series have been pub-
lished. The purpose of this study was to investigate
and report the clinicopathological features of small-
bone GCTs and to identify previously unreported
characteristics of the disease.
Materials and methods
Clinical information on 11 cases of small-bone GCT
was collected from several institutions using a
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stained glass slide specimens were also obtained
from those institutions. The term ‘small bone’ was
deﬁned as a carpal bone or any bone distal to the
carpal in the hand, and talus or any bone distal to the
talus in the foot. The analyzed parameters included
gender, age, affected bone(s), symptoms, primary
surgical procedure, recurrence, and metastasis. Image
evaluation was performed on the basis of the Cam-
panacci stage classiﬁcation (1). Hematoxylin-
eosin (H-E) staining was performed for pathological
evaluation. In addition, since p63 has been reported
as a useful marker for the differential diagnosis of
GCT (2,3), p63 immunostaining was performed to
conﬁrm the reliability of the initial diagnosis. The
p63-positive cases were classiﬁed into three categories
on the basis of the ratio of p63-positive nuclei among
total mononuclear cells: slightly positive (£5% posi-
tive nuclei); positive (5–30% positive nuclei); and
highly positive (‡30% positive nuclei). The p63
immunostaining was also performed for specimens
of other osseous tumors that were collected for the
purpose of comparison. These included conventional
GCT of the femur or tibia (n = 5), giant cell reparative
granuloma (GCRG) of the metacarpal bone (n = 1),
and solid variant of aneurysmal bone cyst (solid
variant ABC) of the humerus (n = 1).
Results
Information was obtained from ﬁve male and six
female cases with a mean age of 24.7 years (range
9–60 years) at initial diagnosis. The bones affected
were metacarpals (n = 5), metatarsals (n = 1), prox-
imal phalanx of the hand (n = 1), proximal phalanx of
the foot (n = 1), middle phalanx of the hand (n = 1),
talus (n = 1), and cuboid (n = 1). Subjective symptoms
at initial examination included pain only (n = 9),
swelling only (n = 1), and swelling with pain
(n = 1). With respect to radiographic staging, two,
six, and three cases corresponded to stages 1, 2, and
3 of the Campanacci classiﬁcation (1), respectively.
The radiographic appearances were conﬁrmed in
four short tubular bones and two tarsal bones. The
distribution of the intraosseous lesions of the short
tubular bone was as follows: two lesions were present
between the epiphysis and metaphysis, one between
the epiphysis and diaphysis (Figure 1A), and one in
the diaphysis (Figure 1B). The center of the lesion
was eccentric in cases of GCT of the talus and the
cuboid (Figure 2). Three cases showed markedly
expanded cortex.
Primary surgical procedures included curettage
with bone grafting (n = 2), curettage followed by
ethanol and phenol adjuvant therapy as well as
bone grafting (n = 3), curettage and bone cementing
(n = 1), en bloc resection (n = 4), and amputation
(n = 1) (Table I). There were two cases of recurrence,
one of which had been treated with curettage and
bone grafting as the primary procedure. Although this
case was treated with curettage followed by ethanol
and phenol adjuvant therapy as a secondary proce-
dure following the ﬁrst episode of recurrence, the
tumor recurred for the third time after 20 months.
Metastatic lesions developed in the lungs of one
patient, who subsequently died of the disease 13 years
after primary surgery.
The authors were able to conﬁrm the histological
ﬁndings of nine cases with the help of a pathologist.
During H-E staining, the typical histological charac-
teristics of bone GCT were recognized in ﬁve cases,
A B
Figure 1. Radiograph of GCT involving the distal fourth metatarsal
bone (A) and diaphysis of the fourth metacarpal bone (B). Both
lesions are purely lytic with partially sclerotic rim and markedly
expanded cortical bone, but with no cortical destruction. The
centersofthelesionsappeartobecentrallylocatedwithinthebones.
A B
Figure 2. Radiograph of GCT involving the talus (A) and cuboid
(B). As in Figure 1, both lesions are purely lytic with partially
sclerotic rim, although the expansion of bone is not prominent. The
lesions appear eccentric.
266 M. Yanagisawa et al.and two showed secondary ABC-like characteristics
along with the typical GCT characteristics. Although
it was difﬁcult to distinguish the typical characteristics
of GCT in two cases, they were not excluded from this
study.
During p63 immunostaining, ﬁve cases were
weakly positive (Figure 3A), three were positive,
and one was highly positive; the highly positive case
had two episodes of recurrence (case 7) (Figure 3B).
Five cases of GCT affecting the femur or tibia were
subjected to p63 immunostaining for comparison;
four were positive and one was highly positive. In
addition, GCRG in the metacarpal bone and solid
variant of ABC in the humerus demonstrated p63
negativity (data not shown).
Discussion
Small-bone GCT cases account for only 4% of all
GCT cases in Japan (4). Unni (5) and Campanacci
(6) reported the incidence of small-bone GCT among
all GCTs as 3% in USA and 4.5% in Italy, respec-
tively. These ﬁndings indicate that racial differences
may not affect the incidence of small-bone GCT.
The main subjective symptom was pain, similar
to that observed in conventional GCT cases. A
notable radiographic characteristic feature was the
marked expansion of the cortical bone, particularly
in the short tubular bones (Figure 2). This ﬁnd-
ing may be explained by occupation of the nar-
row bone marrow cavity by the tumor in its early
stage, resulting in multidirectional expansion of
the cortex.
The tendency of small-bone GCT to develop in
younger individuals has been reported (7,8). The
results of our study are concurrent with these
ﬁndings, with a 45% incidence (5 of 11 cases) of
small-bone GCTs in individuals below 20 years of
age; moreover, only 1 patient was above 40 years
of age. On the other hand, the incidence of all
GCTs in individuals below 20 years of age is 16%
in Japan (4).
It has also been reported that GCT of the hand
adopts a more aggressive clinical course than that of
GCTs occurring in more central locations (9). In
contrast, Malawer and Vance reported that GCT in
the tarsal bones was not as aggressive and carried a
good prognosis (10). In addition, O’Keefe et al. also
reported that GCT of the foot was less aggressive
(11). Two patients among those who were followed
up for over two years in our study had episodes of
recurrence; the primary lesion was in the hand in both
cases. In addition, one case of primary GCT of the
hand developed lung metastasis. The results of our
study were therefore concurrent with those of the
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Small-bone GCT 267above-mentioned authors that GCT of the hand has a
more aggressive biologic potential.
Dicksonetal.andLeeetal.reportedthatp63expresses
in the mononuclear cells of GCT, and that ﬁnding was
useful to distinguish GCT from other giant cell-rich
tumors such as ABC and chondroblastoma (2,3). All
small-boneGCTsexcept twounexamined specimensin
this study showed varying degrees of p63 positivity. On
the other hand, GCRG, which is sometimes difﬁcult to
distinguishfromsmall-boneGCT(12,13),andthesolid
variant of ABC in the humerus demonstrated p63 neg-
ativity. Therefore, p63 immunostaining appears to be
helpful in the differentiation of small-bone GCT from
GCRG. Furthermore, two episodes of recurrence after
primary surgery were documented for one case of GCT
ofthehandthatwashighlypositiveforp63.Althoughwe
were unable to perform p63 immunostaining in the
other case of recurrence as well as for the case with
lung metastasis, the above-mentioned ﬁnding suggests
that p63 may be useful not only for the differential
diagnosis of GCT but also for prognostication of the
aggressiveness of small-bone GCT as a biomarker. Fur-
ther investigations are needed to conﬁrm the correlation
between p63 expression and the clinical behavior of
small-bone GCT.
In summary, small-bone GCT tends to develop in
individuals below 20 years of age. GCT of the hand
may be biologically more aggressive than that occur-
ring in other sites. The p63 immunostaining may be
useful for both differential diagnosis and prediction of
clinical behavior of small-bone GCTs.
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